Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 230 results for "zydus group cadila healthcare"

Torrent Group & Cadila Healthcare among top political donors from Gujarat during 2013-14
Indian Express

CADILA HEALTHCARE : Torrent, Cadila among donors to Cong, NCP

Ahmedabad: The Torrent group and Cadila Healthcare were among the top donors from Gujarat to have made donations to Congress and NCP ahead of 2014 Lok Sabha elections, a report by advocacy group Association for Democratic Reforms (ADR) said. The ... 4 Traders, 1 month ago

Buy Cadila Healthcare; target of Rs 1715: Firstcall

Firstcall Research report on Cadila Healthcare "For the Second quarter ended Sept 30, 2014, Zydus Cadila reported sales of Rs. 21080.00 mn, up by 20.68% from Rs. 17467.90 mn in the corresponding quarter of the previous year on a consolidated ...
 Moneycontrol.com1 month ago Cadila launches first cheaper version of a multi-billion dollar drug  VC Circle1 month ago Cadila Healthcare Q2 net up 52% at Rs 278 crore  The Financial Chronicle2 months ago
Livemint.com

Cadila recalls 19,536 bottles of cough treatment drug in US

dia | New Delhi January 8, 2015 Last Updated at 18:45 IST Drug firm Cadila Healthcare is voluntarily recalling 19,536 bottles of benzonatate capsules, used to treat coughs, in the US due to "wet and/or leaking capsules". According to a notification ...
 Business Standard India3 weeks ago Cadila Healthcare recalls 19,536 bottles of cough treatment drug in US  Economic Times3 weeks ago Cadila recalls 15,144 bottles of hypertension drug in US  Business Standard India1 month ago Cadila Recalls 15,144 Bottles of Anti-Hypertension Drug in US  NDTV Profit1 month ago
[x]  

Cadila Healthcare advances despite recalling cough treatment drug in US

Cadila Healthcare is currently trading at Rs. 1705.65, up by 59.40 points or 3.61% from its previous closing of Rs. 1646.25 on the BSE. The scrip opened at Rs. 1662.35 and has touched a high and low of Rs. 1717.95 and Rs. 1662.35 respectively. So ...
 Arihant Capital2 weeks ago Cadila Healthcare rises on launching world's first bio-similar of Adalimumab  Arihant Capital1 month ago

Zydus Cadila Launches Adalimumab Biosimilar in India

Zydus Cadila is the first company to launch a biosimilar of Amgen's Adalimumab, a top selling therapy for rheumatoid arthritis and other autoimmune disorders. The biosimilar has been approved by the Drug Controller General of India and will be ...
 Contract Pharma1 month ago Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab  News-Medical.Net1 month ago Zydus Launches World's First Biosimilar of Adalimumab  BioSpace1 month ago Zydus launches worlds first biosimilar of Adalimumab  India Infoline1 month ago
[x]  

Zydus begins Phase - III study of Saroglitazar in NASH, a liver disease caused by obesity, diabetes and lipid disorders

Details Category: Small Molecules Published on Sunday, 11 January 2015 21:06 Hits: 45 January 9, 2015 I The Zydus group announced the initiation of Phase III clinical trials to study its effect in adult nonalcoholic steatohepatitis (NASH) ...
 PipelineReview2 weeks ago
Financial Express

The Gujarat Model: Is it the way forward?

Gujarat has done very well in some sectors but with its health indicators still lagging behind, will it be the blueprint for the rest of India? By Raelene Kambli Sickle Cell Anemia Control Programme Gujarat's model of development has been ...
 Financial Express1 week ago

Fortified OTC play to keep J&J healthy

hnson & Johnson's acquisition of fruit-based electrolyte drink, ORSL, also gives it access to the nutrition drinks space Viveat Susan Pinto | Mumbai November 16, 2014 Last Updated at 21:50 IST The recent acquisition of the electrolyte brand ORSL by ...
 Business Standard India2 months ago
[x]  

Supernus Files Trokendi XR Patent Infringement Lawsuit - Analyst Blog

Supernus Pharmaceuticals, Inc. ( SUPN ) has filed a patent infringement lawsuit against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited accusing them of infringement of three patents covering Supernus' antiepileptic drug, Trokendi XR.
 Nasdaq2 months ago Supernus Sues Zydus for Infringement of Trokendi XR(R) Patents  Stockwatch2 months ago Supernus Pharmaceuticals Sues Zydus Pharmaceuticals (USA) Inc. For Infringement Of Trokendi XR(R) Patents  BioSpace2 months ago Supernus Pharmaceuticals : Sues Zydus for Infringement of Trokendi XR(R) Patents  4 Traders2 months ago
[x]  
AhmedabadMirror.com

No economic development without good health: WHO

To boost the healthcare sector in Gujarat the state government signed more than 270 MoUs with hospitals and pharmaceutical companies at the seventh Vibrant Gujarat Global Investor Summit on Monday. The major companies included Gujarat Cancer ...
 AhmedabadMirror.com2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - zydus group cadila healthcare
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less